363 related articles for article (PubMed ID: 29903988)
1. Oncolytic Viruses for Multiple Myeloma Therapy.
Calton CM; Kelly KR; Anwer F; Carew JS; Nawrocki ST
Cancers (Basel); 2018 Jun; 10(6):. PubMed ID: 29903988
[TBL] [Abstract][Full Text] [Related]
2. Advances in viral oncolytics for treatment of multiple myeloma - a focused review.
Sarwar A; Hashim L; Faisal MS; Haider MZ; Ahmed Z; Ahmed TF; Shahzad M; Ansar I; Ali S; Aslam MM; Anwer F
Expert Rev Hematol; 2021 Dec; 14(12):1071-1083. PubMed ID: 34428997
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic virotherapy for multiple myeloma.
Stief AE; McCart JA
Expert Opin Biol Ther; 2008 Apr; 8(4):463-73. PubMed ID: 18352850
[TBL] [Abstract][Full Text] [Related]
4. The Use of Oncolytic Viruses in the Treatment of Multiple Myeloma.
Stewart G; Chantry A; Lawson M
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830842
[TBL] [Abstract][Full Text] [Related]
5. Systemic virotherapy for multiple myeloma.
Oliva S; Gambella M; Boccadoro M; Bringhen S
Expert Opin Biol Ther; 2017 Nov; 17(11):1375-1387. PubMed ID: 28796556
[TBL] [Abstract][Full Text] [Related]
6. Virotherapy in Germany-Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies.
Nettelbeck DM; Leber MF; Altomonte J; Angelova A; Beil J; Berchtold S; Delic M; Eberle J; Ehrhardt A; Engeland CE; Fechner H; Geletneky K; Goepfert K; Holm PS; Kochanek S; Kreppel F; Krutzke L; Kühnel F; Lang KS; Marchini A; Moehler M; Mühlebach MD; Naumann U; Nawroth R; Nüesch J; Rommelaere J; Lauer UM; Ungerechts G
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452286
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic Virotherapy for Cancer: Clinical Experience.
Chaurasiya S; Fong Y; Warner SG
Biomedicines; 2021 Apr; 9(4):. PubMed ID: 33924556
[TBL] [Abstract][Full Text] [Related]
8. Poxvirus oncolytic virotherapy.
Torres-Domínguez LE; McFadden G
Expert Opin Biol Ther; 2019 Jun; 19(6):561-573. PubMed ID: 30919708
[TBL] [Abstract][Full Text] [Related]
9. Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β.
Naik S; Nace R; Barber GN; Russell SJ
Cancer Gene Ther; 2012 Jul; 19(7):443-50. PubMed ID: 22522623
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic vaccinia virus: from bedside to benchtop and back.
Thorne SH
Curr Opin Mol Ther; 2008 Aug; 10(4):387-92. PubMed ID: 18683104
[TBL] [Abstract][Full Text] [Related]
11. Targeting pediatric cancer stem cells with oncolytic virotherapy.
Friedman GK; Cassady KA; Beierle EA; Markert JM; Gillespie GY
Pediatr Res; 2012 Apr; 71(4 Pt 2):500-10. PubMed ID: 22430386
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic Poxviruses.
Chan WM; McFadden G
Annu Rev Virol; 2014 Sep; 1(1):119-141. PubMed ID: 25839047
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic viruses: A novel treatment strategy for breast cancer.
Javanbakht M; Tahmasebzadeh S; Cegolon L; Gholami N; Kashaki M; Nikoueinejad H; Mozafari M; Mozaffari M; Zhao S; Khafaei M; Izadi M; Fathi S; Akhavan-Sigari R
Genes Dis; 2023 Mar; 10(2):430-446. PubMed ID: 37223527
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic viruses: From bench to bedside with a focus on safety.
Buijs PR; Verhagen JH; van Eijck CH; van den Hoogen BG
Hum Vaccin Immunother; 2015; 11(7):1573-84. PubMed ID: 25996182
[TBL] [Abstract][Full Text] [Related]
15. Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis.
Gebremeskel S; Nelson A; Walker B; Oliphant T; Lobert L; Mahoney D; Johnston B
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33722907
[TBL] [Abstract][Full Text] [Related]
16. The emerging role of oncolytic virus therapy against cancer.
Russell L; Peng KW
Chin Clin Oncol; 2018 Apr; 7(2):16. PubMed ID: 29764161
[TBL] [Abstract][Full Text] [Related]
17. Promising oncolytic agents for metastatic breast cancer treatment.
Cody JJ; Hurst DR
Oncolytic Virother; 2015; 4():63-73. PubMed ID: 27512671
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic Virotherapy and Microenvironment in Multiple Myeloma.
Marchica V; Costa F; Donofrio G; Giuliani N
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33668361
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses.
Guo ZS; Thorne SH; Bartlett DL
Biochim Biophys Acta; 2008 Apr; 1785(2):217-31. PubMed ID: 18328829
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic virotherapy for multiple myeloma: past, present, and future.
Thirukkumaran CM; Morris DG
Bone Marrow Res; 2011; 2011():632948. PubMed ID: 22046569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
